Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medium- and long-term efficacy of 0.05% cyclosporine A eye drops in Sjogren's syndrome–related dry eye
ChiCTR2500111481Phase 4Completed
- Sponsor
- Tongji Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cyclosporine in dry eye syndrome (DED) and Sjögren's syndrome (4 arms), sponsored by Tongji Hospital. Primary endpoints: Ocular Surface Disease Index score and Corneal fluorescein staining score. Started Oct 2025; status: completed.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)Sjögren's syndrome
Beyond the preview
Go deeper on ChiCTR2500111481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111481.